0.000
0.00 (0.00%)
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 0.910 |
| Margin Keuntungan | -16.74% |
| Margin Operasi (TTM) | -16.30% |
| EPS Cair (TTM) | -1.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -47.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.30% |
| Nisbah Semasa (MRQ) | 5.18 |
| Pulangan Atas Aset (ROA TTM) | -2.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Qilian International Holding Gr | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 0.75 |
|
Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 77.45% |
| % Dimiliki oleh Institusi | 0.04% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |